PRESS-RELEASE ·Filed May 4, 2026
Press release · FDA
Actionable Insight • Neutral
Monitor ASCO 2026 for Phase 1 data; no near-term catalyst. Clinical success is binary with high risk. Small cap with history of negative stock moves on prior neutral news.
Final — all horizons settled through T+60d
NXTC ▼ -43.72% at T+60d
NEUTRAL call -43.72% · α vs SPY -45.58% · entry $8.92 → $5.02
T+1d
+4.48%
call +4.48% · α +3.69%
$9.32
settled 6mo ago
T+5d
+9.64%
call +9.64% · α +6.71%
$9.78
settled 6mo ago
T+20d
-62.11%
call -62.11% · α -67.75%
$3.38
settled 5mo ago
T+60d
-43.72%
call -43.72% · α -45.58%
$5.02
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
NextCure announced initiation of dose optimization for its CDH6-directed ADC SIM0505 in platinum-resistant ovarian cancer, with FDA Fast Track designation. Phase 1 data will be presented at ASCO 2026, but no financial or efficacy data was released.
Key Facts
- FDA granted Fast Track designation for SIM0505 in platinum-resistant ovarian cancer
- Dose optimization portion of Phase 1 study initiated in PROC patients
- Phase 1 data readout planned for ASCO 2026
- NextCure holds exclusive global rights for SIM0505 except China, Hong Kong, Macau, Taiwan
Financial Impact
No financial data disclosed; $34M market cap biotech with no approved products
Risk Factors
- Clinical trial failure or underwhelming efficacy/safety data
- Cash burn without revenue; potential need for dilutive financing
- High volatility typical for micro-cap biotech
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286574 |
17 reports for NXTC
75% Hit rate @ T+60 Went positive at some point 6 of 6 best @ T+60▲ +74.85%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.22 (−3.95%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.22 (+22.36%) |
Aug 4, 2026 11w ago | 425 | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.22 (+3.88%) |
Jul 14, 2026 14w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.22 (−20.59%) |
Jul 14, 2026 14w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.22 (+20.59%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.22 (+54.59%) |
Showing 10 of 17
US Market Status
Market Closed — Opens in 3h 16m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers